Skip to main
  1. Stocks
  2. HealthEquity
  3. Forecast
HQY

HealthEquity (HQY) Stock Forecast & Price Target

HealthEquity (HQY) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 70%
Hold 0%
Sell 0%
Strong Sell 10%

Bulls say

HealthEquity is positioned to benefit from a durable expansion in its addressable market as high-deductible plans rise, HSA eligibility broadens, and the company continues to take share in a fragmented industry where it already has ~20%+ market share. The F2Q:27 print reinforced that thesis with revenue of $350.7M (+7.6% y/y), adjusted EBITDA of $167M (+11% y/y), a record ~48% EBITDA margin, and HSA members up 8% y/y, while new HSA sales rose 24% y/y and guidance for F2027E was raised. It also has multiple operating levers for further upside, including Enhanced Rates on ~$2.3B of HSA cash, only ~9% investing penetration, and technology/AI investments that are improving service efficiency, engagement, and margin expansion.

Bears say

HealthEquity is viewed negatively because its growth is exposed to a young, highly competitive HSA market with significant regulatory uncertainty, shifting healthcare rules, and rising adoption of alternative payment methods that could pressure utilization and balance growth. The company also faces material operational and financial risks from cyberattacks and fraud, including a class action lawsuit and millions in costs from a recent sophisticated attack, while ongoing investment in cybersecurity, R&D, and acquisitions may weigh on margins and execution. In addition, falling interest rates, a weakening labor market with unemployment above 5%, and recession-driven job losses could slow HSA contributions and reduce enhanced cash balance returns, reinforcing the downside case of 5% topline growth and 200 bps of margin contraction in 2027.

HealthEquity (HQY) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 70% recommend Buy, 0% suggest Holding, 0% advise Selling, and 10% predict a Strong Sell.

This aggregate rating is based on analysts' research of HealthEquity and is not a guaranteed prediction by Public.com or investment advice.

HealthEquity (HQY) Analyst Forecast & Price Prediction

Get the latest HealthEquity (HQY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HealthEquity (HQY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About HealthEquity (HQY) Forecast

Analysts have given HealthEquity (HQY) a Buy based on their latest research and market trends.

According to 10 analysts, HealthEquity (HQY) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $116.30, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $116.30, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

HealthEquity (HQY)


HealthEquity (HQY) Analyst Forecast & Price Prediction

Get the latest HealthEquity (HQY) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in HealthEquity (HQY)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HQY stock data and trends